Literature DB >> 27902508

Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.

Chasity D Andrews1, Leslie St Bernard, Amanda Yee Poon, Hiroshi Mohri, Natanya Gettie, William R Spreen, Agegnehu Gettie, Kasi Russell-Lodrigue, James Blanchard, Zhi Hong, David D Ho, Martin Markowitz.   

Abstract

OBJECTIVE: We evaluated the effectiveness of cabotegravir (CAB; GSK1265744 or GSK744) long acting as preexposure prophylaxis (PrEP) against intravenous simian immunodeficiency virus (SIV) challenge in a model that mimics blood transfusions based on the per-act probability of infection.
DESIGN: CAB long acting is an integrase strand transfer inhibitor formulated as a 200 mg/ml injectable nanoparticle suspension that is an effective PrEP agent against rectal and vaginal simian/human immunodeficiency virus transmission in macaques.
METHODS: Three groups of rhesus macaques (n = 8 per group) were injected intramuscularly with CAB long acting and challenged intravenously with 17 animal infectious dose 50% SIVmac251 on week 2. Group 1 was injected with 50 mg/kg on week 0 and 4 to evaluate the protective efficacy of the CAB long-acting dose used in macaque studies mimicking sexual transmission. Group 2 was injected with 50 mg/kg on week 0 to evaluate the necessity of the second injection of CAB long acting for protection against intravenous challenge. Group 3 was injected with 25 mg/kg on week 0 and 50 mg/kg on week 4 to correlate CAB plasma concentrations at the time of challenge with protection. Five additional macaques remained untreated as controls.
RESULTS: CAB long acting was highly protective with 21 of the 24 CAB long-acting-treated macaques remaining aviremic, resulting in 88% protection. The plasma CAB concentration at the time of virus challenge appeared to be more important for protection than sustaining therapeutic plasma concentrations with the second CAB long acting injection.
CONCLUSION: These results support the clinical investigation of CAB long acting as PrEP in people who inject drugs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27902508      PMCID: PMC5263045          DOI: 10.1097/QAD.0000000000001343

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

1.  GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects.

Authors:  William Spreen; Susan L Ford; Shuguang Chen; David Wilfret; David Margolis; Elizabeth Gould; Stephen Piscitelli
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

2.  A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.

Authors:  Chasity D Andrews; Yun Lan Yueh; William R Spreen; Leslie St Bernard; Mar Boente-Carrera; Kristina Rodriguez; Agegnehu Gettie; Kasi Russell-Lodrigue; James Blanchard; Susan Ford; Hiroshi Mohri; Cecilia Cheng-Mayer; Zhi Hong; David D Ho; Martin Markowitz
Journal:  Sci Transl Med       Date:  2015-01-14       Impact factor: 17.956

3.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

4.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

Authors:  David A Margolis; Cynthia C Brinson; Graham H R Smith; Jerome de Vente; Debbie P Hagins; Joseph J Eron; Sandy K Griffith; Marty H St Clair; Marita C Stevens; Peter E Williams; Susan L Ford; Britt S Stancil; Melinda M Bomar; Krischan J Hudson; Kimberly Y Smith; William R Spreen
Journal:  Lancet Infect Dis       Date:  2015-07-19       Impact factor: 25.071

6.  Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Authors:  Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje
Journal:  N Engl J Med       Date:  2015-02-05       Impact factor: 91.245

Review 7.  Estimating per-act HIV transmission risk: a systematic review.

Authors:  Pragna Patel; Craig B Borkowf; John T Brooks; Arielle Lasry; Amy Lansky; Jonathan Mermin
Journal:  AIDS       Date:  2014-06-19       Impact factor: 4.177

8.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

9.  Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

Authors:  Chasity D Andrews; William R Spreen; Hiroshi Mohri; Lee Moss; Susan Ford; Agegnehu Gettie; Kasi Russell-Lodrigue; Rudolf P Bohm; Cecilia Cheng-Mayer; Zhi Hong; Martin Markowitz; David D Ho
Journal:  Science       Date:  2014-03-04       Impact factor: 47.728

10.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

View more
  15 in total

1.  Pharmacokinetic and Chemical Synthesis Optimization of a Potent d-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery.

Authors:  Joseph S Redman; J Nicholas Francis; Robert Marquardt; Damon Papac; Alan L Mueller; Debra M Eckert; Brett D Welch; Michael S Kay
Journal:  Mol Pharm       Date:  2018-02-22       Impact factor: 4.939

2.  Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.

Authors:  Raphael J Landovitz; Deborah Donnell; Meredith E Clement; Brett Hanscom; Leslie Cottle; Lara Coelho; Robinson Cabello; Suwat Chariyalertsak; Eileen F Dunne; Ian Frank; Jorge A Gallardo-Cartagena; Aditya H Gaur; Pedro Gonzales; Ha V Tran; Juan C Hinojosa; Esper G Kallas; Colleen F Kelley; Marcelo H Losso; J Valdez Madruga; Keren Middelkoop; Nittaya Phanuphak; Breno Santos; Omar Sued; Javier Valencia Huamaní; Edgar T Overton; Shobha Swaminathan; Carlos Del Rio; Roy M Gulick; Paul Richardson; Philip Sullivan; Estelle Piwowar-Manning; Mark Marzinke; Craig Hendrix; Maoji Li; Zhe Wang; Jeanne Marrazzo; Eric Daar; Aida Asmelash; Todd T Brown; Peter Anderson; Susan H Eshleman; Marcus Bryan; Cheryl Blanchette; Jonathan Lucas; Christina Psaros; Steven Safren; Jeremy Sugarman; Hyman Scott; Joseph J Eron; Sheldon D Fields; Nirupama D Sista; Kailazarid Gomez-Feliciano; Andrea Jennings; Ryan M Kofron; Timothy H Holtz; Katherine Shin; James F Rooney; Kimberly Y Smith; William Spreen; David Margolis; Alex Rinehart; Adeola Adeyeye; Myron S Cohen; Marybeth McCauley; Beatriz Grinsztejn
Journal:  N Engl J Med       Date:  2021-08-12       Impact factor: 176.079

3.  Long-Acting Injectable Human Immunodeficiency Virus Pre-Exposure Prophylaxis Preferred Over Other Modalities Among People Who Inject Drugs: Findings from a Qualitative Study in California.

Authors:  Angela R Bazzi; Chad J Valasek; Samantha A Streuli; Carlos F Vera; Alicia Harvey-Vera; Morgan M Philbin; Katie B Biello; Alexis M Roth; Steffanie A Strathdee; Heather A Pines
Journal:  AIDS Patient Care STDS       Date:  2022-06-21       Impact factor: 5.944

4.  Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

Authors:  Philip L Tzou; Diane Descamps; Soo-Yon Rhee; Dana N Raugi; Charlotte Charpentier; Nuno Taveira; Robert A Smith; Vicente Soriano; Carmen de Mendoza; Susan P Holmes; Geoffrey S Gottlieb; Robert W Shafer
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

5.  In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Authors:  Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

6.  Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir.

Authors:  Nagsen Gautam; JoEllyn M McMillan; Devendra Kumar; Aditya N Bade; Qiaoyu Pan; Tanmay A Kulkarni; Wenkuan Li; Brady Sillman; Nathan A Smith; Bhagya L Dyavar Shetty; Adam Szlachetka; Benson J Edagwa; Howard E Gendelman; Yazen Alnouti
Journal:  Nat Commun       Date:  2021-06-08       Impact factor: 14.919

Review 7.  Long-acting injectable cabotegravir for the prevention of HIV infection.

Authors:  Meredith E Clement; Ryan Kofron; Raphael J Landovitz
Journal:  Curr Opin HIV AIDS       Date:  2020-01       Impact factor: 4.061

Review 8.  Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals.

Authors:  Matthew R Beymer; Ian W Holloway; Craig Pulsipher; Raphael J Landovitz
Journal:  Curr HIV/AIDS Rep       Date:  2019-08       Impact factor: 5.495

9.  Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Authors:  Raphael J Landovitz; Sue Li; Beatriz Grinsztejn; Halima Dawood; Albert Y Liu; Manya Magnus; Mina C Hosseinipour; Ravindre Panchia; Leslie Cottle; Gordon Chau; Paul Richardson; Mark A Marzinke; Craig W Hendrix; Susan H Eshleman; Yinfeng Zhang; Elizabeth Tolley; Jeremy Sugarman; Ryan Kofron; Adeola Adeyeye; David Burns; Alex R Rinehart; David Margolis; William R Spreen; Myron S Cohen; Marybeth McCauley; Joseph J Eron
Journal:  PLoS Med       Date:  2018-11-08       Impact factor: 11.069

10.  Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.

Authors:  Tian Zhou; Hang Su; Prasanta Dash; Zhiyi Lin; Bhagya Laxmi Dyavar Shetty; Ted Kocher; Adam Szlachetka; Benjamin Lamberty; Howard S Fox; Larisa Poluektova; Santhi Gorantla; JoEllyn McMillan; Nagsen Gautam; R Lee Mosley; Yazen Alnouti; Benson Edagwa; Howard E Gendelman
Journal:  Biomaterials       Date:  2017-10-15       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.